Sanofi Says Rilzabrutinib Receives Orphan Drug Status in Japan
MT Newswires Live
Yesterday
Sanofi (SNY) said Monday that Japan's Ministry of Health, Labour and Welfare has granted orphan drug designation to its experimental medicine rilzabrutinib for the treatment of IgG4-related disease.
The company said orphan drug status in Japan is given to treatments targeting rare diseases or conditions with significant unmet medical needs.
Sanofi said rilzabrutinib was evaluated in a phase 2 trial, where 52 weeks of treatment reduced disease flare-ups and other key disease markers, while lowering patients' need for glucocorticoid therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.